Knowledge Hub

China Multiple Sclerosis Industry Drug Forecast and Market Analysis to 2024

Press Release   •   Oct 06, 2016 04:53 EDT

Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.

Sales of DMT products in China were estimated to be $61.3m in 2014, making it the second smallest MS market behind India. GlobalData anticipates steep growth to occur mid-forecast resulting from the launch of the first oral DMTs in China. Currently only four DMTs are available, with mitoxantrone being used off-label for MS in China. As such, the anticipated approval of two oral agents will not only provide added convenience for patients but will increase the diversity of treatment options, leading to a notable rise in treatment rates.

Download Sample copy of this Report at :


- Overview of MS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in China including product MScription, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in China from 2014-2024.

- Analysis of the impact of key events as well the drivers and restraints affecting China MS market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for MS.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2014-2024 in China.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 10

2 Introduction 11

2.1 Catalyst 11

2.2 Related Reports 12

3 Disease Overview 13

3.1 Etiology and Pathophysiology 13

3.1.1 Etiology 13

3.1.2 Pathophysiology 14

3.2 Classification 15

3.2.1 Relapse-Remitting Multiple Sclerosis 15

3.2.2 Secondary Progressive Multiple Sclerosis 16

3.2.3 Primary Progressive Multiple Sclerosis 16

3.2.4 Progressive Relapsing Multiple Sclerosis 16

3.3 Symptoms 17

3.4 Prognosis 18

3.5 Quality of Life 19

4 Disease Management 20

4.1 Diagnosis 20

4.2 Treatment Overview 24

4.2.1 Management of Acute Relapse 26

4.2.2 Treatment with Disease-Modifying Therapies 26

4.2.3 Symptomatic Therapies 31

4.3 China 32

4.3.1 Forecast 32

4.3.2 Key Events 35

4.3.3 Drivers and Barriers 35

5 Competitive Assessment 36

5.1 Overview 36

5.2 Product Profiles - Major Injectable Brands 38

5.2.1 Betaseron 38

5.2.2 Avonex 43

5.2.3 Rebif 48

5.2.4 Copaxone 52

5.2.5 Tysabri 58

5.2.6 Lemtrada 63 is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.